Home Crystal structure of (E)-3-methoxy-N′-(1-(pyridin-2-yl)ethylidene)benzohydrazide, C15H15N3O2
Article Open Access

Crystal structure of (E)-3-methoxy-N′-(1-(pyridin-2-yl)ethylidene)benzohydrazide, C15H15N3O2

  • Valeri V. Mossine ORCID logo EMAIL logo , Steven P. Kelley and Thomas P. Mawhinney
Published/Copyright: March 25, 2020

Abstract

C15H15N3O2, orthorhombic, Pca21 (no. 29), a = 7.9831(2) Å, b = 10.6486(3) Å, c = 15.7222(4) Å, V = 1336.53(6) Å3, Z = 4, Rgt(F) = 0.0340, wRref(F2) = 0.0799, T = 100 K.

CCDC no.: 1989321

Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless prism
Size:0.28 × 0.22 × 0.09 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.09 mm−1
Diffractometer, scan mode:Bruker APEX-II, φ and ω
θmax, completeness:29.7°, >99%
N(hkl)measured, N(hkl)unique, Rint:34842, 3790, 0.049
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3385
N(param)refined:186
Programs:Bruker [1], SHELX [2], [3], Olex2 [4], Crystal Explorer [5], Mercury [6]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
O10.65856(15)0.64702(11)0.53292(9)0.0163(3)
O21.13033(16)0.94314(11)0.64302(8)0.0172(3)
N10.81973(18)0.47369(13)0.50812(9)0.0123(3)
N20.69467(17)0.42449(13)0.45744(9)0.0122(3)
N30.5631(2)0.13527(14)0.37099(10)0.0164(3)
C10.7893(2)0.58803(16)0.54361(10)0.0115(3)
C20.9256(2)0.63898(15)0.59947(11)0.0114(3)
C30.9580(2)0.76818(15)0.59386(11)0.0120(3)
C41.0831(2)0.81951(16)0.64451(11)0.0132(3)
C51.1709(2)0.74460(17)0.70209(11)0.0156(3)
C61.1347(2)0.61830(17)0.70823(12)0.0157(3)
C71.0126(2)0.56340(15)0.65637(10)0.0134(3)
C81.0461(2)1.02502(16)0.58479(12)0.0190(4)
C90.7113(2)0.31023(15)0.43228(11)0.0123(3)
C100.5685(2)0.26067(16)0.38103(10)0.0125(3)
C110.4476(2)0.34046(17)0.34663(11)0.0169(4)
C120.3153(3)0.28838(19)0.30172(13)0.0231(4)
C130.3086(3)0.15935(19)0.29134(14)0.0233(4)
C140.4345(3)0.08763(17)0.32668(13)0.0198(4)
C150.8537(2)0.22489(17)0.45435(14)0.0225(4)
H10.916(3)0.438(2)0.5112(14)0.015*
H30.8954400.8196790.5561000.014*
H51.2554510.7805160.7369650.019*
H61.1933830.5679250.7482080.019*
H70.9895010.4760390.6600060.016*
H8A1.0932791.1097190.5893220.029*
H8B0.9264141.0275560.5985590.029*
H8C1.0609330.9938300.5266310.029*
H110.4557320.4288180.3538440.020*
H120.2303800.3405050.2783720.028*
H130.2196250.1212040.2606560.028*
H140.429805−0.0008200.3191740.024*
H15A0.8778960.2314530.5152940.034*
H15B0.9531120.2492190.4217130.034*
H15C0.8233110.1380990.4404950.034*

Source of material

To a suspension of 831 mg (5 mmoles) m-anisic hydrazide in 15 mL 90% aqueous EtOH were added 606 mg (561 μL, 5 mmoles) 2-acetylpyridine, and the reaction mixture was stirred for 6 h at 70 °C. The resulting clear solution was brought to 4 °C and left for 2 days to deposit crystals as colorless prisms.

Experimental details

The hydrazide H1 atom was located in difference-Fourier maps while all other hydrogen atoms were initially placed in calculated positions. Thermal parameters were constrained to ride on the carrier atoms (Uiso(methine H) = 1.2Ueq and Uiso(methyl H) = 1.5Ueq). Due to a high uncertainty on the Flack parameter (0.279), no attempt to model inversion twinning was made.

Comment

One particular interest to hydrazide-hydrazones, a versatile group of organic molecules, stems from their high affinity to iron, which makes these structures potential antimicrobial [7], [8], anticancer [9], or neuroprotective [10] agents. As a part of our search for inhibitors of cytotoxic virulence factors from drug-resistant bacteria [11], we have prepared the title compound, a structural analogue of a series of hydrazide-hydrazones that are pharmacologically active in vivo.

The title compound crystallizes in the orthorhombic Pca21 space group, with four equivalent molecules per unit cell. The asymmetric unit of the title structure contains one molecule of 2-acetylpyridine m-anisoyl hydrazone (2APymAH), shown in the upper part of the figure. The valence bond lengths and angles are in the expected ranges. The major portion of the molecule is approximately flat: all but three atoms, O1, H8C, and H15B, are located within 1 Å of the mean molecular plane. The pyridyl and the anisyl ring planes are at 10.0° and 13.3° to the molecular plane, respectively. The conventional hydrogen bonding in crystal structure of 2APymAH is limited to only one intermolecular heteroatom contact (N1⋯O1 = 3.020(2) Å, H1⋯O1 = 2.17(2) Å, N1—H1⋯O1 = 174(2)°) shown in the upper part of the figure. In the crystal, infinite chains of the H-bonds propagate in the [100] direction. In addition, two short intermolecular contacts of the C—H⋯O/N type, which satisfy to the directionality condition (angle C—H⋯O/N > 120°) and which are shown in the figure as dotted lines, may contribute to the stability of the molecular packing in the 2APymAH crystal, as well. The crystal structure lacks any strong π-π stacking interactions, with the shortest contact between the pirydyl (ring 1) and the anisyl (ring 2) rings Cg1⋯Cg2′ = 5.1198(11) Å (′ = −1/2 + x, 1 − y, z). In addition, a short C5—H5⋯Cg1′′ (′′ = 2 − x, 1 − y, 1/2 + z) contact is present in the crystal structure, as well.

To account for all interactions involved in the build-up of the crystal structure, we have performed DFT calculations, at the B3LYP/6-31G(d,p) theory level [5], [12], of the electrostatic, dispersion, polarization, and repulsion energies in the 2APymAH crystal structure. According to the calculations, the interactions from hydrogen-bonded pairs of molecules contributed about 50% to the lattice energy, with the dispersion energy providing most for the attractive forces between neighbouring molecules of 2APymAH (i.e. Eelstat = −54 kJ/mol, Edisp = −75.2 kJ/mol for x + 1/2, −y, z). The spatial distribution of the energetically most significant interactions is illustrated in the lower part of the figure, showing the interactions energy framework as blue cylinders penetrating the crystal lattice of 2APymAH. The cylinders connect centroids of the interacting molecules, and their diameters are proportional to the total energies of the interactions, with the 8 kJ/mol cut-off, for clarity. The most extensive intermolecular interactions occur in the H-bonding direction parallel to [100]. To estimate the lattice energy, all total energies of unique pairwise interactions between molecules were summed up, thus yielding Elattice = −164 kJ/mol for the 2APymAH crystal.

Acknowledgements

We gratefully acknowledge financial support by the University of Missouri Agriculture Experiment Station Chemical Laboratories and by the National Institute of Food and Agriculture (grant MO-HABC0002).

References

1. Bruker Axs Inc., Apex3 v. 2016.9-0 and SAINT v. 8.37A. Madison, WI, USA (2016).Search in Google Scholar

2. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

3. Sheldrick, G. M.: Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Search in Google Scholar PubMed PubMed Central

4. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 42 (2009) 339–341.10.1107/S0021889808042726Search in Google Scholar

5. MacKenzie, C. F.; Spackman, P. R.; Jayatilaka, D.; Spackman, M. A.: CrystalExplorer model energies and energy frameworks: extension to metal coordination compounds, organic salts, solvates and open-shell systems. IUCrJ 4 (2017) 575–587.10.1107/S205225251700848XSearch in Google Scholar PubMed PubMed Central

6. Macrae, C. F.; Bruno, I. J.; Chisholm, J. A.; Edgington, P. R.; McCabe, P.; Pidcock, E.; Rodriguez-Monge, L.; Taylor, R.; van de Streek, J.; Wood, P. A.: Mercury CSD 2.0 – new features for the visualization and investigation of crystal structures. J. Appl. Crystallogr. 41 (2008) 466–470.10.1107/S0021889807067908Search in Google Scholar

7. Narang, R.; Narasimhan, B.; Sharma, S.: A review on biological activities and chemical synthesis of hydrazide derivatives. Curr. Med. Chem. 19 (2012) 569–612.10.2174/092986712798918789Search in Google Scholar PubMed

8. Rzhepishevska, O.; Hakobyan, S.; Ekstrand-Hammarstroem, B.; Nygren, Y.; Karlsson, T.; Bucht, A.; Elofsson, M.; Boily, J.-F.; Ramstedt, M.: The gallium(III)-salicylidene acylhydrazide complex shows synergistic anti-biofilm effect and inhibits toxin production by Pseudomonas aeruginosa. J. Inorg. Biochem. 138 (2014) 1–8.10.1016/j.jinorgbio.2014.04.009Search in Google Scholar PubMed

9. Lovejoy, D. B.; Richardson, D. R.: Iron chelators as anti-neoplastic agents: Current developments and promise of the PIH class of chelators. Curr. Med. Chem. 10 (2003) 1035–1049.10.2174/0929867033457557Search in Google Scholar PubMed

10. Richardson, D. R.: Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. N. Y. Acad. Sci. 1012 (2004) 326–341.10.1196/annals.1306.026Search in Google Scholar PubMed

11. Mossine, V. V.; Waters, J. K.; Chance, D. L.; Mawhinney, T. P.: Transient proteotoxicity of bacterial virulence factor pyocyanin in renal tubular epithelial cells induces ER-related vacuolation and can be efficiently modulated by iron chelators. Toxicol. Sci. 154 (2016) 403–415.10.1093/toxsci/kfw174Search in Google Scholar PubMed PubMed Central

12. Thomas, S. P.; Spackman, P. R.; Jayatilaka, D.; Spackman, M. A.: Accurate lattice energies for molecular crystals from experimental crystal structures. J. Chem. Theory Comput. 14 (2018) 1614–1623.10.1021/acs.jctc.7b01200Search in Google Scholar PubMed

Received: 2020-02-18
Accepted: 2020-03-10
Published Online: 2020-03-25
Published in Print: 2020-06-25

©2020 Valeri V. Mossine et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Articles in the same Issue

  1. Frontmatter
  2. Crystal structure of bis [1-(phenylsulfonyl)-2-(1-(pyrazin-2-yl)ethylidene)hydrazin-1-ido-κ3N,N′,O]cobalt(II), C24H22N8O4S2Co
  3. The crystal structure of 1,3-bis(4-(methoxycarbonyl)benzyl)-2-methyl-1H-benzo[d]imidazol-3-ium bromide, C26H25BrN2O4
  4. Crystal structure of {tris((1H-benzo[d]imidazol-2-yl)methyl)amine-κ4N,N′,N′′,N′′′}-(nitrito-κ2O,O′)nickel(II) perchlorate – ethanol (1/1), C26H27ClN8NiO7
  5. Crystal structure of catena-poly[aqua[(μ2-4,5-dicarboxylato-2-(2-carboxylatophenyl)imidazol-1-ido-κ4N,O,O′:N′)](μ2-4,4′-bipyridine-κ2N:N′)dicopper(II)], C22H14Cu2N4O7
  6. Crystal structure of chlorido-tris(4-methylbenzyl-κC)-(triphenylarsine oxide-κO)tin(IV), C42H42AsClOSn
  7. The crystal structure of 4,4′-bipyridinium bis(3-carboxy-2-nitrobenzoate) tetrahydrate, C13H13N2O8
  8. Crystal structure of 1-(3-chlorophenyl)-4-(4-(((2,3-dihydro-1H-inden-5-yl)oxy)methyl)phenethyl)piperazine, C28H31ClN2O
  9. Crystal structure of catena-poly[diaqua-bis(μ2-5,5′-(1H-imidazole-4,5-diyl)bis(tetrazol-2-ido)-κ4N,N′:N′′,N′′′)magnesium], C10H8N20O2Mg
  10. The crystal structure of (E)-2-((2-hydroxy-4-ethoxybenzylidene)amino)-2-methylpropane-1,3-diol monohydrate, C13H21NO5
  11. Crystal structure of catena-poly[diaqua-(μ2-bipyridine-κ2N:N′)-bis(3,5-dichloroisonicotinato-κO)cadmium(II)] dihydrate, C22H20CdCl4N4O8
  12. The crystal structure of 4-(4-chlorophenyl)cyclohexane-1-carboxylic acid, C13H15ClO2
  13. Redetermination of the crystal structure of yttrium(III) trinitrate(V) pentahydrate, Y(NO3)3 ⋅ 5 H2O, H10N3O14Y
  14. Crystal structure of catena-poly[di-μ2-chlorido-1,10-phenanthroline-κ2N,N′-cadmium(II)], C12H8Cl2CdN2
  15. Crystal structure of 4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzoic acid, C13H9F3N2O3
  16. Crystal structure of 3-acetyl-4-hydroxybenzoic acid, C18H16O8
  17. Crystal structure of bis(N,2-bis(4-ethoxybenzylidene)hydrazine-1-carbohydrazonothioato-κ2N,S)nickel(II) — N,N-dimethylformamide (1/2), C44H56N10S2O6Ni
  18. The crystal structure of 5-chloro-4,6-dimethoxypyrimidin-2-amine, C6H8ClN3O2
  19. Crystal structure of poly[aqua-(μ4-benzene-1,2,4,5-tetracarboxylato-κ4O,O′,O′′,O′′′)bis(μ2-1-(4-(1H-imidazol-1-yl)benzyl)-1H-1,2,4-triazole-κ2N:N)dinickel(II)], NiC17H14N5O5
  20. Crystal structure of poly[aqua(5-dimethylamino)naphthalene-1-sulfonato-κ2N:O)(μ2-4,4′-bipyridyl -κ2N:N′)silver(I)], C44H44Ag2N6O8S2
  21. Crystal structure of 1-[3-(trifluoromethyl)cinnamoyl]-3-(pyridin-2-yl-κN)pyrazole-κ2N-bis(2-phenylpyridinato-k2C,N)iridium(III) hexafluorophosphate complex, [C40H28F3IrN5O]PF6
  22. Crystal structure of catena-poly[aqua(μ6-piperazine-1,4-bisethanesulfonato-κ6N:N′:O:O′:O′′:O′′′)(μ2-pyrazinyl-κ2N:N′)disilver(I)sesquihydrate], C12H30Ag2N4O11S2
  23. Crystal structure of (E)-1-(2-nitrophenyl)-N-(o-tolyl)methanimine, C14H12N2O2
  24. Crystal structure of 4′-amino-3′,5′-diisopropyl-(1,1′-biphenyl)-4-carbonitrile, C19H22N2
  25. The crystal structure of poly[bis(N,N-dimethylformamide-κ1O)-tetrakis(μ2-cyanido-κ2C:N)dinickel(II)], C10H14N6O2Ni2
  26. Crystal structure of rac-trans-N,N′-bis(3-bromo-5-chlorosalicylidene)-1,2-cyclohexanediamine, C20H18Br2Cl2N2O2
  27. Crystal structure of rac-trans-N,N′-bis(3,5-dibromosalicylidene)-1,2-cyclohexanediamine, C20H18Br4N2O2
  28. The crystal structure of (dichromato-κ2O,O′)bis(1,10-phenanthroline-κ2N,N′)nickel(II), C12H16N4O7Cr2Ni
  29. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridozincate(II) monohydrate, C10H18Cl4ZnN2O
  30. Crystal structure of bis(μ2-azido-k2N,N)-bis(2-amino-1-(N-(3-bromosalicylaldiminato))ethane)-dicopper(II), C20H18Br4N2O2
  31. Crystal structure of (η6-1-methyl-4-isopropylbenzene)-[5-bromo-2-(2-pyridyl)phenyl-κ2C,N]-chloro-ruthenium(II), C21H21BrClNRu
  32. Crystal structure of N-(methyl(oxo)(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-λ6-sulfanylidene)cyanamide, C10H10F3N3OS
  33. Crystal structure of 6,6′-((cyclohexane-1,2-diylbis(azanylylidene))bis(methanylylidene))bis(2-bromo-4-chlorophenolato-κ4N,N′,O,O′)nickel(II), C20H16Br2Cl2NiN2O2
  34. Redetermination of the crystal structure of catena-poly[aqua-(1,10-phenanthroline-κ2N,N′)-(μ2-tetraoxidomolybdato(VI)-κ2O:O′)manganese(II) monohydrate, C12H12N2O6MoMn
  35. The crystal structure tetrakis(μ2-o-chlorobenzoato-κ2O:O′)-bis(methanol-κ1O)dirhodium(II), C30H24Cl4O10Rh2
  36. Crystal structure of bis(2,3-diphenyltetrazolidine-5-thione-κ1S)-(nitrato-κ1O)-(nitrato-κ2O,O′)lead(II), C26H20N10O6S2Pb
  37. Crystal structure of bis(3-bromo-N-(1-(3-methylpyrazin-2-yl)ethylidene)benzohydrazonato-κ3O,N,N′)cadmium(II) hemihydrate, C28H25N8O2.5Br2Cd
  38. Crystal structure of catena-poly[tetrakis(μ2-trifluoroacetato-κ2O:O′)(μ2-2,5-dimethylpyrazine-κ2N,N′)dicopper(II)], C7H4CuF6NO4
  39. The crystal structure of catena-poly[bis[3-azoniapentane-1,5-diammonium][bis(μ4-oxo)-tetrakis(μ3-oxo)-heptakis(μ2-oxo)-tetradecaoxo-octa-molybdenum] dihydrate], (C8H36N6O29Mo8)n
  40. Crystal structure of tetraaqua-bis(2-((3,5,6-trichloropyridin-2-yl)oxy)acetato-κO)-nickel(II)—diaqua-bis(2-((3,5,6-trichloropyridin-2-yl)oxy)acetato-nickel(II), C28H24Cl12N4Ni2O18
  41. The crystal structure of bis(2-hydroxypyrimidinium) pentachloridobismuthate(III), (C4N2H5O)2BiCl5
  42. The crystal structure of catena-poly[(μ2-4,4′-dipyridine-κ2N,N′)-bis(3,5,6-trichloropyridine-2-oxyacetato-κO)-bis(ethanol-κO)nickel(II)], C28H26Cl6N4NiO8
  43. Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-chlorophenyl)sulfonyl)-3,5-bis(4-fluorobenzylidene)piperidin-4-one-dichloromethane (1/1), C26H20Cl3F2NO3S
  44. The crystal structure of 5-bromopicolinic acid monohydrate, C6H6BrNO3
  45. The crystal structure of 2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-8H-indeno[1,2-d]thiazole, C25H17BrFN3S
  46. The crystal structure of catena-poly[(μ2-2-((3-bromo-2-oxidobenzylidene)amino)acetato-κ4O,N,O′:O′′)-(dimethylformamide-κ1O)]zinc(II), C12H13N2O4BrZn
  47. Crystal structure of aqua-azido-κ1N-(6,6′-((propane-1,3-diylbis(azanylylidene))bis(methanylylidene))bis(3-bromophenolato)-κ4N,N′,O,O′iron(III), C17H16Br2FeN5O3
  48. The crystal structure of tris(1-ethylimidazole-κ1N)-(sulfato-κ2O,O′)vanadium(IV), C15H24N6O5SV
  49. Crystal structure of (E)-3-methoxy-N′-(1-(pyridin-2-yl)ethylidene)benzohydrazide, C15H15N3O2
  50. Crystal structure of dichloro-bis-(1-butyl-1H-benzo[d]imidazole)-nickel(II), C22H28Cl2N4Ni
  51. The crystal structure of 2-(2,3-dimethoxyphenyl)-3-hydroxy-4H-chromen-4-one, C17H14O5
  52. The crystal structure of 5-(2-(4-fluorophenyl)hydrazono)-4-methyl-2-((3-(5-methyl-1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene) hydrazono)-2,5-dihydrothiazole dimethylformamide monosolvate, C30H25FN10S⋅C3H7NO
  53. The crystal structure of 1,8-bis(pyridin-4-ylethynyl)anthracene-1,2,4,5-tetrafluoro-3,6-diiodobenzene (2/1), C62H32F4I2N4
  54. The crystal structure of 3,6-di-tert-butyl-1,8-diiodo-9-methyl-9H-carbazole, C21H25I2N
  55. The crystal structure of 8-((4-chlorophenylamino)methylene)-6,10-dioxaspiro[4.5]decane-7,9-dione, C15H14ClNO4
  56. The crystal structure of catena-poly[oktaaqua-bis(μ2-4,4′-ethene-1,2-diyldipyridine-κ2N:N′)-(μ2-3,3′-(1-oxidodiazene-1,2-diyl)diphthalato-κ2O:O′)dicobalt(II)] dihydrate, C28H36N4O19Co2
  57. Crystal structure of (E)-1-(2-cyano-3-oxo-1-phenylprop-1-en-1-yl)-3,7-diphenylindolizine-6-carbonitrile, C31H19N3O
  58. Crystal structure of 1,1′-bis(diphenylphosphino)ferrocene-(1,1′-bis(diphenylphosphino)ferrocene-κ2P,P′)-(O-isobutyl sulfurodithioito-κ2S,S′)copper(I), C39H37CuFeOP2S2
  59. Crystal structure of poly[(5-bimethylamino-1-naphthalenesulfonato-κO)-(μ3-hexamethylenetetramino-κ3N:N′:N′′)silver(I)] dihydrate, C36H52Ag2N10O8S2
  60. Crystal structure of poly[μ2-diaqua-(μ2-2-amino-4,5-dicyano-κ2N:N′-imidazol-1-ide)sodium(I)], C5H6N5O2Na
  61. Crystal structure of (1,3-propanediamine-κ2N,N′)(N-(3-aminopropyl)-α-methyl aspartato-κ4N,N′,O,O′)cobalt(III) chloride, C11H24ClCoN4O4
  62. Crystal structure and anti-inflammatory activity of (3E,5E)-3,5-bis(4-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)piperidin-4-one-dichloromethane (1/1), C26H20Cl2F3NO3S
  63. Crystal structure of (S)-(+)-1-cyclohexylethylaminium chloride, C8H18NCl
  64. The crystal structure of tris(nitrato-κ2O,O′)-bis(4,4,5,5-tetramethyl-2-(o-pyridyl)imidazoline-1-oxyl 3-oxide-κ2N,O)yttrium(III), C24H32N9O13Y
  65. Hydrogen bonding versus packing effects in the crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetraiodidozincate(II), C10H16I4ZnN2
  66. Dimerization of 2-[(2-((2-aminophenyl)thio)phenyl)amino]-cyclohepta-2,4,6-trien-1-one through hydrogen bonding, C19H16N2OS
  67. Crystal structure of 1-(4-chloro-phenyl)-7-ethoxyl-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, C18H12ClF2NO4
  68. Crystal structure of 7-ethoxy-6,8-difluoro-4-oxo-1-pyridin-2-ylmethyl-1,4-dihydro-quinoline-3-carboxylic acid, C18H14F2N2O4
  69. Crystal structure of octahydro-7aR,8′R-dimethylspiro[isobenzofuran-4(1H), 4′ (3′H)-[1H-7,9a]methanocyclohepta[c]pyran]-1′,3, 9′ (3aH,4′aH)-trione, C20H26O5
  70. Crystal structure of bis(5-ethoxy-2-(((1-hydroxy-2-methyl-3-oxidopropan-2-yl)imino)methyl)phenolato-κ3N,O,O’)manganese(IV) – methanol (1/1), C27H38MnN2O9
  71. Crystal structure of 8a,8a′′-oxybis(8aH-8,9-dioxa-3a1λ4-aza-8aλ4-borabenzo[fg]tetracene), C34H22B2N2O5
  72. Crystal structure of bromido-triphenyl-(triphenylarsine oxide-κO)tin(IV), C36H30AsBrOSn
  73. Crystal structure of catena-poly[chlorido-(μ2-formato-κ2O:O′)-(1,10-phenathroline-κ2N,N′)copper(II)], C26H18Cl2Cu2N4O4
  74. The crystal structure of poly[(μ10-5-carboxyisophthalato-κ10O)disodium], C9H4Na2O6
  75. The crystal structure of 3,5-difluoroisonicotinic acid, C6H3F2NO2
  76. The crystal structure of ethyl-1-(N-(adamantan-1-yl)-carbamothioyl)piperidine-4-carboxylate, C19H30N2O2S
  77. Crystal structure of 5-methyl-3-phenyl-1-tosyl-1,2,3,4-tetrahydropyridine, C19H21NO2S
  78. Crystal structure of bis((3-chlorosalicylidene)-ethylenediaminato-κ4N,N′,O,O′)nickel (II), C16H12Cl2NiN2O2
  79. Crystal structure of (E)-N′-(2-chloro-6-hydroxybenzylidene)-4-hydroxybenzohydrazide — dihydrofuran-2(3H)-one (1/1), C18H17ClN2O5
  80. Crystal structure of bis((3-bromosalicylidene)-ethylenediaminato-κ4N,N′,O,O′) nickel (II), C16H12Br2NiN2O2
  81. Crystal structure of trimethylsulfoxonium tetrachloridocobaltate(II) [(CH3)3SO]2CoCl4
Downloaded on 11.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2020-0097/html
Scroll to top button